Stockreport
Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ... [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
The transaction was executed at an average price of $85.18 per share, resulting in a total value of $3,009,831.38. Biomarin Pharmaceutical Inc, headquartered in San Rafael, California, is a biotechnology company focused on the development and commercialization of innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio includes products and product candidates that target various diseases, including hemophilia, short stature due to achondroplasia, and phenylketonuria (PKU), among others. Warning! GuruFocus has detected 3 Warning Sign with BMRN. Over the past year, the insider has sold a total of 47,341 shares of Biomarin Pharmaceutical Inc and has not made any purchase of shares. The recent sale by Henry Fuchs represents a continuation of this selling trend. The insider transaction history for Biomarin Pharmaceutical Inc shows a pattern of 19 insider sells and no insider buys over the past year, indicating
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.[MarketBeat]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.[MarketBeat]
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance][Yahoo! Finance]
- Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Citigroup Inc. from $94.00 to $91.00. They now have a "neutral" rating on the stock.[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 4/26/24 - Form 10-Q
- 4/24/24 - Form 8-K
- 4/23/24 - Form 8-K
- BMRN's page on the SEC website
- More